Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Nvidia Options Price in $280 Billion Earnings Swing 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Tesla Raises Cybertruck Prices by $5,000 in US 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Add as a preferred source on Google
LOS ANGELES, CA, April 27, 2018 -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible Notes, through a Regulation D 506(b) offering to qualified buyers. The Notes would be convertible into Hoverink common stock and would have a two-year term. the Notes and the common stock issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes. Hoverink Biotechnologies, Inc., headquartered in Los Angeles, CA, is an independent preclinical biopharmaceutical company. The Company develops, manufactures, and commercializes pharmaceutical preparations and drug treatment for age-related diseases, cancer, mental illnesses, and gastrointestinal and oncological disorders. Hoverink Biotechnologies serves patients in the United States.
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, uncertainties related to the offering of the notes. Actual results could differ materially. for more information on Hoverink Biotechnologies, Inc. please visit the company's web site at http://www.hoverinkbiotech.yolasite.com/ or call the Hoverink Biotechnologies Corporate Communications Department at 866-443-4666 EXT 113
Contact: Cyrus Sajna Vice-President Hoverink Biotechnologies Inc, 1801 CENTURY PARK EAST, 24TH FLOOR LOS ANGELES, CA 90067 [email protected] 866-443-4666
